Evidence map›Paper›PMID 25693799›Full record

ArticleMolecular & cellular proteomics : MCP2015

Large-Scale Interlaboratory Study to Develop, Analytically Validate and Apply Highly Multiplexed, Quantitative Peptide Assays to Measure Cancer-Relevant Proteins in Plasma.

Susan E Abbatiello, Birgit Schilling, D R Mani, Lisa J Zimmerman, Steven C Hall, Brendan MacLean, Matthew Albertolle, Simon Allen, Michael Burgess, Michael P Cusack and 31 more

Open access · hybridAbstract read
In one paragraph

Article in Molecular & cellular proteomics : MCP, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 80 papers.

0numbers the graph read from it
0cells of the map it votes in
80citing papers in PubMed
0.2field-weighted citation impact, top 48% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

80 citing papers in PubMed, 6 citations in OpenAlex.

  1. Molecular & cellular proteomics : MCP · 2018
    Trial
  2. Article
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

20 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors at 16 institutions in 2 countries.

Susan E AbbatielloFrom the Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142;
Birgit SchillingBuck Institute for Research on Aging, Novato, California 94945;
D R ManiFrom the Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142;
Lisa J ZimmermanDepartment of Biochemistry, Vanderbilt University School of Medicine, and the Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232;
Steven C HallDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143;
Brendan MacLeanDepartment of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195;
Matthew AlbertolleDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143;
Simon AllenDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143;
Michael BurgessFrom the Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142;
Michael P CusackBuck Institute for Research on Aging, Novato, California 94945;
Mousumi GoshMemorial Sloan-Kettering Cancer Center, New York, New York 10065;
Victoria HedrickPurdue University, West Lafayette, Indiana 47907;
Jason M HeldBuck Institute for Research on Aging, Novato, California 94945;
H Dorota InerowiczPurdue University, West Lafayette, Indiana 47907;
Angela JacksonUniversity of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8 CAN;
Hasmik KeshishianFrom the Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142;
Christopher R KinsingerNational Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892;
John LyssandKimmel Center for Biology and Medicine at the Skirball Institute, New York University School of Medicine, New York, New York 10016;
Lee MakowskiArgonne National Laboratory (currently at Northeastern University, Boston Massachusetts 02115;
Mehdi MesriNational Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892;
Henry RodriguezNational Cancer Institute, National Institutes of Health, Bethesda, Maryland 20892;
Paul RudnickNational Institute of Standards and Technology, Gaithersburg, Maryland 20899;
Pawel SadowskiKimmel Center for Biology and Medicine at the Skirball Institute, New York University School of Medicine, New York, New York 10016;
Nell SedranskNational Institute of Statistical Sciences, Research Triangle Park, North Carolina 27709;
Kent ShaddoxDepartment of Biochemistry, Vanderbilt University School of Medicine, and the Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232;
Stephen J SkatesBiostatistics Center, Massachusetts General Hospital, Boston, Massachusetts 02114;
Eric KuhnFrom the Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142;
Derek SmithUniversity of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8 CAN;
Jeffery R WhiteakerFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Corbin WhitwellDepartment of Biochemistry, Vanderbilt University School of Medicine, and the Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232;
Shucha ZhangFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Christoph H BorchersUniversity of Victoria-Genome BC Proteomics Centre, Victoria, British Columbia V8Z 7X8 CAN;
Susan J FisherDepartment of Obstetrics, Gynecology, and Reproductive Sciences, University of California, San Francisco, San Francisco, California 94143;
Bradford W GibsonBuck Institute for Research on Aging, Novato, California 94945;
Daniel C LieblerDepartment of Biochemistry, Vanderbilt University School of Medicine, and the Jim Ayers Institute for Precancer Detection and Diagnosis, Vanderbilt-Ingram Cancer Center, Nashville, Tennessee 37232;
Michael J MacCossDepartment of Genome Sciences, University of Washington School of Medicine, Seattle, Washington 98195;
Thomas A NeubertKimmel Center for Biology and Medicine at the Skirball Institute, New York University School of Medicine, New York, New York 10016;
Amanda G PaulovichFred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Fred E RegnierPurdue University, West Lafayette, Indiana 47907;
Paul TempstMemorial Sloan-Kettering Cancer Center, New York, New York 10065;
Steven A CarrFrom the Broad Institute of MIT and Harvard, Cambridge, Massachusetts 02142; scarr@broad.mit.edu.
Broad Institute · USBuck Institute for Research on Aging · USUniversity of California, San Francisco · USVanderbilt University · USFred Hutch Cancer Center · USNew York University · USPurdue University West Lafayette · USUniversity of Victoria · CAMemorial Sloan Kettering Cancer Center · USNational Cancer Institute · USUniversity of Washington · USMassachusetts General Hospital · USNational Institute of Standards and Technology · USNational Institute of Statistical Sciences · USNational Institutes of Health · USNortheastern University · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI ANIRBAN MAITRA · 1985 to 2026
$83.1M
Proteo-genomic Discovery, Prioritization and Verification of Cancer BiomarkersU24CA160034 · NCI · BROAD INSTITUTE, INC. · PI CARR, STEVEN A, PAULOVICH, AMANDA G · 2011 to 2016
$16.2M
Measuring Cancer Biomarker Candidates by Targeted MS and Ab EnrichmentU24CA126476 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI CARR, STEVEN A · 2006 to 2010
$14.6M
Vanderbilt Proteome Characterization CenterU24CA159988 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI LIEBLER, DANIEL C · 2011 to 2016
$13.9M
Assessment of serum peptide profiling to detect cancer-specific patternsU24CA126485 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI TEMPST, PAUL · 2006 to 2010
$8.0M
Skyline Targeted Proteomics EnvironmentR01GM103551 · NIGMS · UNIVERSITY OF WASHINGTON · PI MACCOSS, MICHAEL · 2012 to 2020
$3.4M
AB SCIEX QTRAP 5500 LC MS/MS systemS10RR027953 · NCRR · BUCK INSTITUTE FOR RESEARCH ON AGING · PI GIBSON, BRADFORD WAYNE · 2010 to 2010
$500k
Triple Quadrupole (Q-Trap) Mass SpectrometerS10RR024604 · NCRR · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI NEUBERT, THOMAS A · 2007 to 2007
$414k
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016087NCI NIH HHS U24 CA126476NCI NIH HHS U24 CA126485NCI NIH HHS U24 CA159988NCI NIH HHS U24CA159988NCI NIH HHS U24 CA160034NCI NIH HHS U24CA160034NCRR NIH HHS S10 RR024604NCRR NIH HHS S10 RR027953NIGMS NIH HHS R01 GM103551PHS HHS U24 126477PHS HHS U24 126479PHS HHS U24 126480
6 · The paper itself

Abstract

There is an increasing need in biology and clinical medicine to robustly and reliably measure tens to hundreds of peptides and proteins in clinical and biological samples with high sensitivity, specificity, reproducibility, and repeatability. Previously, we demonstrated that LC-MRM-MS with isotope dilution has suitable performance for quantitative measurements of small numbers of relatively abundant proteins in human plasma and that the resulting assays can be transferred across laboratories while maintaining high reproducibility and quantitative precision. Here, we significantly extend that earlier work, demonstrating that 11 laboratories using 14 LC-MS systems can develop, determine analytical figures of merit, and apply highly multiplexed MRM-MS assays targeting 125 peptides derived from 27 cancer-relevant proteins and seven control proteins to precisely and reproducibly measure the analytes in human plasma. To ensure consistent generation of high quality data, we incorporated a system suitability protocol (SSP) into our experimental design. The SSP enabled real-time monitoring of LC-MRM-MS performance during assay development and implementation, facilitating early detection and correction of chromatographic and instrumental problems. Low to subnanogram/ml sensitivity for proteins in plasma was achieved by one-step immunoaffinity depletion of 14 abundant plasma proteins prior to analysis. Median intra- and interlaboratory reproducibility was <20%, sufficient for most biological studies and candidate protein biomarker verification. Digestion recovery of peptides was assessed and quantitative accuracy improved using heavy-isotope-labeled versions of the proteins as internal standards. Using the highly multiplexed assay, participating laboratories were able to precisely and reproducibly determine the levels of a series of analytes in blinded samples used to simulate an interlaboratory clinical study of patient samples. Our study further establishes that LC-MRM-MS using stable isotope dilution, with appropriate attention to analytical validation and appropriate quality control measures, enables sensitive, specific, reproducible, and quantitative measurements of proteins and peptides in complex biological matrices such as plasma.

Indexed as

Chromatography, LiquidHumansIsotope LabelingMass SpectrometryNeoplasm ProteinsNeoplasmsPeptidesProteomicsReproducibility of ResultsNeoplasm ProteinsPeptides

Identifiers

PMID25693799
PMCPMC4563721
OpenAlexW1521887573

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.